Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 408 participants.

Also called NCT06350890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 408 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06350890
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06350890. Randomized; double masking; primary purpose treatment. Start 2023-11-05 (actual); primary completion 2024-12-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
Acronym
SYMPHONY-1
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
HTD1801
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06350890
Content hash
d18cab552c8c6ee8cf8e8a3f5981b512f59a27cd4df38b32a71a27396dfd840c